Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) have been given a consensus rating of “Buy” by the eighteen analysts that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $115.60.
Several brokerages recently weighed in on BMRN. Citigroup reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a report on Thursday, May 23rd. BidaskClub cut shares of BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a report on Friday, July 26th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $133.00 target price on shares of BioMarin Pharmaceutical in a report on Monday, August 5th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $128.00 target price on shares of BioMarin Pharmaceutical in a report on Wednesday, July 10th.
Shares of NASDAQ BMRN traded up $1.17 during midday trading on Friday, hitting $73.97. The company’s stock had a trading volume of 17,463 shares, compared to its average volume of 1,042,843. The business’s fifty day simple moving average is $76.16 and its two-hundred day simple moving average is $83.95. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.11 and a quick ratio of 2.79. BioMarin Pharmaceutical has a 1 year low of $70.82 and a 1 year high of $106.74. The firm has a market capitalization of $13.21 billion, a price-to-earnings ratio of -224.09 and a beta of 1.32.
BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.16). The firm had revenue of $388.00 million during the quarter, compared to analyst estimates of $415.03 million. BioMarin Pharmaceutical had a negative net margin of 7.19% and a negative return on equity of 3.12%. The firm’s revenue was up 4.0% compared to the same quarter last year. During the same period last year, the business earned ($0.09) EPS. Analysts anticipate that BioMarin Pharmaceutical will post -0.03 EPS for the current fiscal year.
In other BioMarin Pharmaceutical news, Director V Bryan Lawlis sold 3,750 shares of the business’s stock in a transaction on Monday, June 17th. The shares were sold at an average price of $81.08, for a total transaction of $304,050.00. Following the sale, the director now directly owns 27,340 shares in the company, valued at approximately $2,216,727.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. BB&T Securities LLC raised its stake in shares of BioMarin Pharmaceutical by 4.0% during the 2nd quarter. BB&T Securities LLC now owns 3,447 shares of the biotechnology company’s stock worth $295,000 after buying an additional 132 shares during the last quarter. Berman Capital Advisors LLC raised its stake in shares of BioMarin Pharmaceutical by 56.8% during the 1st quarter. Berman Capital Advisors LLC now owns 417 shares of the biotechnology company’s stock worth $36,000 after buying an additional 151 shares during the last quarter. Avestar Capital LLC raised its stake in shares of BioMarin Pharmaceutical by 36.9% during the 2nd quarter. Avestar Capital LLC now owns 750 shares of the biotechnology company’s stock worth $44,000 after buying an additional 202 shares during the last quarter. First Mercantile Trust Co. raised its stake in shares of BioMarin Pharmaceutical by 2.6% during the 2nd quarter. First Mercantile Trust Co. now owns 8,116 shares of the biotechnology company’s stock worth $695,000 after buying an additional 206 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its stake in shares of BioMarin Pharmaceutical by 4.0% during the 1st quarter. Janney Montgomery Scott LLC now owns 6,940 shares of the biotechnology company’s stock worth $616,000 after buying an additional 268 shares during the last quarter. Institutional investors own 98.08% of the company’s stock.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Further Reading: How can investors benefit from after-hours trading?
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.